Tybost is owned by Gilead Sciences Inc.
Tybost contains Cobicistat.
Tybost has a total of 4 drug patents out of which 0 drug patents have expired.
Tybost was authorised for market use on 24 September, 2014.
Tybost is available in tablet;oral dosage forms.
Tybost can be used as treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase.
The generics of Tybost are possible to be released after 06 April, 2033.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US8148374||GILEAD SCIENCES INC||Modulators of pharmacokinetic properties of therapeutics|| |
(6 years from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|GILEAD SCIENCES INC||Modulators of pharmacokinetic properties of therapeutics|| |
(7 years from now)
|US10039718||GILEAD SCIENCES INC||Use of solid carrier particles to improve the processability of a pharmaceutical agent|| |
(9 years from now)
|GILEAD SCIENCES INC||Use of solid carrier particles to improve the processability of a pharmaceutical agent|| |
(10 years from now)
|Orphan Drug Exclusivity (ODE)||Aug 22, 2026|
|New Patient Population (NPP)||Aug 22, 2022|
Market Authorisation Date: 24 September, 2014
Treatment: Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic